SCHEMBL4473972

SCHEMBL4473972

CCN(CC)C(=O)c1c2c(c(O)c(=O)n1C)C(=O)N(Cc1ccc(F)cc1)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.41
OPRM1 P35372 7/20 0.40
OPRD1 P41143 7/20 0.40
KCNH2 Q12809 5/20 0.40
LMNA P02545 6/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
HTT P42858 4/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.38
CENPE Q02224 1/20 0.37
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13672777 0.91 AKR1B1 (0.41) AKR1B1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4480852 0.89 CENPE (0.36) AKR1B1KCNH2SMN1; SMN2CENPEMAPT
SCHEMBL4490682 0.89 CENPE (0.40) AKR1B1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4479556 0.88 CENPE (0.44) AKR1B1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL13672778 0.88 AKR1B1 (0.43) AKR1B1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4499878 0.84 AKR1B1 (0.39) AKR1B1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4487792 0.83 THRB (0.46) AKR1B1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4495602 0.83 AKR1B1 (0.40) AKR1B1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL5452304 0.82 ALDH1A1 (0.34) AKR1B1LMNASMN1; SMN2HTTL3MBTL1
SCHEMBL4486193 0.82 TP53 (0.45) AKR1B1LMNASMN1; SMN2HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US claimed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO claimed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-7598264-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
US-20070179196-A1 Hiv integrase inhibitors MERCK SHARP & DOHME CORP. 2007-08-02 US disclosed
EP-1725556-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP disclosed
WO-2005087768-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179196-A1 Hiv integrase inhibitors REV1, TYMP, POLR2H AKR1B1 2248/4885OPRM1 1478/4885OPRD1 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.